夏宁邵

发布时间:2016-07-01         浏览次数:236

Xia, Ning-Shao 夏宁邵,教授 博导

1995-2002, Associate Professor, Xiamen University, 2002-present, Professor and Director, Research Center for Medical Molecular Virology of Fujian Province, 2005-present, Professor and Director, National Institute of Diagnostics  and Vaccine Development in Infectious Diseases.

1995-2002 厦门大学生命科学学院 副教授, 2002-厦门大学生命科学学院教授、博导, 2005-国家传染病诊断试剂与疫苗工程技术研究中心主任,闽江学者特聘教授,国家杰出青年基金获得者。获得国家技术发明二等奖、国家科技进步二等奖、福建省技术发明一等奖等多项科技奖励。

Research Interesting

Research and development of recombinant antigen, vaccine and diagnostic kits related to medical virus, and their molecular biology and immunology study. To facilitate rapid response against newly emerged infectious diseases and forecast of new infections emerging.

医学病毒相关基因工程抗原、诊断试剂、疫苗、单克隆抗体等研发和产业化,以及相关病毒的分子生物学、免疫学基础研究。建立突发传染病应急反应和新发传染病预警技术体系。首次鉴定出戊肝病毒的2个中和表位,建立了完善的大肠杆菌类病毒颗粒表达技术平台,研制成功戊肝疫苗,成为国际上第一个完成三期临床试验申报新药的戊肝疫苗,已获得国内外授权发明专利4项。

Selected Publications:

1.Zhu FC, J Zhang, C Zhou, XF Zhang,SJ Huang, H Wang, CL Yang, HM Jiang, JP Cai,YJ Wang, X Ai, Y Hu, Q Tang, YL Xian, T Wu, YM Li, J Miao, H Ng, JW Shih, Xia NS*. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomized, double-blind placebo-controlled, phase 3 trlial. Lancet, 376:895-902, 2010.

2.Guo QS, Yan Q, Xiong JH, Ge SX, Shih JW, Ng MH, Zhang J, Xia NS*. Prevalence of hepatitis E virus in Chinese blood donors. J Clin Microbiol. 48:317-8, 2010.

3.Zheng ZZ, Miao J, Zhao M, Yeo AET, Yu H, Zhang J and Xia NS*. Role of heat-shock protein 90 in hepatitis E virus capsid trafficking. J Gen Virol,  91, 1728-1736, 2010.

4.Li SW , Seetharaman J. ,  Yang CY, Gu Y , Zhang J , Du HL , Shih JWK , Cl Hew, Sivaraman J , and Xia NS.Dimerization of Hepatitis E Virus Capsid Protein E2s Domain is Essential for Virus-Host Interaction. PLoS Pathogens. 5:e1000537, 2009.

5.Zhang J, CB Liu, RC Li, YM Li, YJ Zheng, YP Li, D Luo, BB Pan, Y Nong, SX Ge, JH Xiong, JW Shih, MH Ng, Xia NS*. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine, 27:1869-1874, 2009.

6.Chen YX, K Qin, WL Wu, GQ Li, J Zhang, HL Du, MH Ng, JWK Shih, JSM Peiris, Y Guan, HL Chen, and Xia NS*. Broad cross protection against H5N1 avian influenza infection using monoclonal antibodies mapping to conserved viral epitopes. Journal of Infection Disease, 199:49-58, 2009.

7.Chen YX, Qin K, Wu WL, Li GQ, Zhang J, Du HL, Ng MH, Shih JWK, Peiris JSM, Guan Y, Chen HL, and Xia NS*. Broad cross protection against H5N1 avian influenza infection using monoclonal antibodies mapping to conserved viral epitopes, J Infect Dis, 199: 199:49-58,2009.

8.He SZ., Miao Ji, Zheng ZZ, Wu T., Xie MH, Tang M., Zhang Jun, Ng MH., Xia NS*. Putative receptor-binding sites of hepatitis E virus. J. General Virol., 89:245-249.2008.

9.Wu T., Wu X.L., Ou S.H., Lin C.X., Cheng T., Li S.W., Ng M.H., Zhang J., Xia NS*. Difference of T cell and B cell activation in two homologous proteins with similar antigenicity but great distinct immunogenicity. Mol Immunol, 44:3161-3266, 2007.